Genmab A/S (GMAB) — SEC Filings
Genmab A/S (GMAB) — 3 SEC filings. Latest: 6-K (May 7, 2026). Includes 3 6-K.
Overview
Genmab A/S (GMAB) is a publicly traded company with 3 SEC filings tracked on ReadTheFiling.
Sentiment Summary
Across 3 filings, the sentiment breakdown is: 3 neutral. The dominant filing sentiment for Genmab A/S is neutral.
Filing Type Overview
Genmab A/S (GMAB) has filed 3 6-K with the SEC between Apr 2026 to May 2026.
Recent SEC Filings (3)
| Date | Form | Description | Risk |
|---|---|---|---|
| May 7, 2026 | 6-K | 6-K Filing | |
| Apr 14, 2026 | 6-K | 6-K Filing | |
| Apr 1, 2026 | 6-K | 6-K Filing |
Frequently Asked Questions
What are the latest SEC filings for Genmab A/S (GMAB)?
Genmab A/S has 3 recent SEC filings from Apr 2026 to May 2026, including 3 6-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GMAB filings?
Across 3 filings, the sentiment breakdown is: 3 neutral. The dominant sentiment is neutral.
Where can I find Genmab A/S SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Genmab A/S (GMAB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Genmab A/S?
Financial highlights for Genmab A/S are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for GMAB?
Investment thesis data for GMAB will be available once enriched filings are processed.
Who are the key executives at Genmab A/S?
Executive information for Genmab A/S is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Genmab A/S stock?
Risk factor analysis for Genmab A/S is available when filings are enriched with AI risk assessment.
What are recent predictions and forward guidance from Genmab A/S?
Forward guidance and predictions for Genmab A/S are extracted from SEC filings as they are enriched.